Navigation Links
ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH

PUNTA DEL ESTE, Uruguay--(BUSINESS WIRE)--Mar 23, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation of data on ZIO-201 at the XXXI World Congress of the International Society of Hematology (ISH) meeting being held in Punta del Este, Uruguay. ZIO-201 is a proprietary form of the therapeutic active metabolite of ifosfamide (IFOS), a drug that is widely used in the treatment of lymphoma. However, IFOS can be problematic in treating lymphoma as certain IFOS metabolites cause debilitating bladder toxicity and confusion. Further, there is a variability in treatment effect associated with the metabolism of IFOS and resistance can develop. The Company believes that ZIO-201 could better deliver the clinical benefits of IFOS without the associated toxicities and the development of resistance.

Data presented at ISH yesterday highlighted that ZIO-201 was 10 to 30 fold more active than IFOS in most in vitro and in vivo models of lymphoma. ZIO-201 also killed IFOS-resistant lymphoma in cancer-bearing mice. In a phase I clinical study, there was little bone marrow toxicity and no hemorrhagic cystitis (bladder toxicity) or central nervous system (CNS) toxicity (confusion). The dose limiting toxicity was characterized by renal electrolyte imbalances. The maximum dose administered was equivalent to high-dose IFOS. Because of the modest bone marrow toxicity, ZIO-201 can be given to patients with bone marrow failure, an important distinction from IFOS in the treatment of patients with lymphoma. A phase II study of ZIO-201 in the treatment of lymphoma will begin later this year.

"These results with ZIO-201 are encouraging," commented Dr. Brian Schwartz, Chief Medical Officer at ZIOPHARM. "Avoiding the more serious toxicities associated with the administration of ifosfamide in addition to having the potential to treat resistant lymphoma patients with ZIO-201 could be an important step forward in r ealizing the broader therapeutic potential for this novel agent."

About ZIO-201

ZIO-201, the active moiety of IFOS, is a bi-functional alkylator that causes irreparable inter-strand DNA cross-linking resulting in cell death. ZIO-201 is equal to or more active than IFOS in diverse cancer models. Unlike IFOS which is a pro-drug, ZIO-201 is directly active against cancer cells. Also, unlike IFOS, ZIO-201 is not metabolized to acrolein or chloracetaldehyde which cause bladder or central nervous system toxicities. ZIO-201 continues in a phase I trial in diverse cancers exploring maximum tolerated dose at alternate schedules. A phase II trial in advanced sarcoma continues to enroll patients. Trials in lymphoma and pediatric cancers are in the advanced planning stage. An oral form of ZIO-201 is in advanced preclinical development.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Compan y's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.



ZIOPHARM Oncology, Inc.
Suzanne McKenna, 646-214-0703
Tina Posterli, 917-322-2565


Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
3. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
4. ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
(Date:11/27/2015)... 2015 Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... Une nouvelle approche consistant à combiner l,immunothérapie au ...    Clinical Cancer Research . ...
(Date:11/27/2015)... DUBLIN , Nov. 26, 2015 /PRNewswire/ ... announced the addition of the "2016 ... by Test, Country Volume and Sales Segment ... Emerging Opportunities" report to their offering. ... the addition of the "2016 Global ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog ... effect tool designed specially for Final Cut Pro X. FCPX users ... the easy-to-use modification controls. Destoying and creating chaotic distortion is now quick and ...
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an ... due to personal experience with a bad back," he said. , This easy-to-use, versatile ... as increases support. It also makes it easier to eat, do other activities and ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of the ... 2016, at Caesars Palace in Las Vegas with a pre-conference session on a ...
Breaking Medicine News(10 mins):